(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110995 A1

(51) International Patent Classification[7]: C07D 207/14, A61K 31/40, A61P 13/00, 25/24, 29/00

(21) International Application Number: PCT/IB2004/001943

(22) International Filing Date: 7 June 2004 (07.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
GB 0314048.0 17 June 2003 (17.06.2003) GB
60/493,126 6 August 2003 (06.08.2003) US

(71) Applicant *(for GB only)*: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for all designated States except GB)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FISH, Paul, Vincent** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **FRAY, Michael, Jonathan** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **LOVERING, Deborah, Jane** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **STOBIE, Alan** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **WAKENHUT, Florian** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **WHITLOCK, Gavin, Alistair** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor Roads, Morris Plains, NJ 07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**
— *with international search report*

(48) Date of publication of this corrected version:
21 April 2005

(15) Information about Correction:
see PCT Gazette No. 16/2005 of 21 April 2005, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS



(I)

(57) Abstract: A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein $R^1$ is H, $C_{1_6}$alkyl, -C(X)Y, $C_{3_8}$cycloalkyl, aryl, het, aryl-$C_{1_4}$alkyl or het-$C_{1_4}$alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1_8allkyl, $C_{1_8}$alkoxy, OH, halo, $CF_3$, $OCF_3$, $SCF_3$, hydroxy-$C_{1_6}$alkyl, $C_{1_4}$alkoxy-$C_{1_6}$alkyl and C1_4alkyl-S-$C_{1_4}$alkyl; $R^2$ is aryl or heteroaryl, each optionally substituted by at least one substituent independently selected from $C_{1_8}$alkyl, $C_{1_8}$alkoxy, OH, halo, $CF_3$, $OCF_3$, SCF3, hydroxy-$C_{1_6}$alkyl, C1_4alkoxy-$C_{1_6}$alkyl and C1_4alkyl-S-$C_{1_4}$alkyl; $R^3$ is $C_{1_6}$alkyl, $C_{3_8}$cycloalkyl, $C_{3_8}$cycloalkyl-$C_{1_6}$alkyl, aryl, het, aryl-$C_{1_4}$alkyl or het-$C_{1_4}$alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from $C_{1_6}$alkyl, $C_{1_6}$alkoxy, OH, halo, $CF_3$, $OCF_3$, $SCF_3$, hydroxy-$C_{1_6}$alkyl, $C_{1_4}$alkoxy - $C_{1_6}$alkyl and $C_{1_4}$alkyl-$SC_{1_4}$alkyl; X is S or O; Y is H, $C_{1_6}$alkyl, aryl, het, aryl-$C_{1_4}$alkyl or het-$C_{1_4}$alkyl; and n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then * represents a chiral center. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.

WO 2004/110995 A1